Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
The current Neurocrine(NBIX) stock price is $146.93, with a market capitalization of 14.64B. The stock trades at a price-to-earnings (P/E) ratio of 35.09.
On 2025-12-25, Neurocrine(NBIX) stock traded between a low of $144.36 and a high of $148.38. Shares are currently priced at $146.93, which is +1.8% above the low and -1.0% below the high.
The Neurocrine(NBIX)'s current trading volume is 359.57K, compared to an average daily volume of 1.06M.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
NBIX News
Neurocrine Biosciences Inc. (NASDAQ:NBIX) on Monday shared data from its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazi...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Neurocrine yesterday and set a price target of $191.00. Claim 70% Off TipRanks This H...
Neurocrine (NBIX) Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adul...
Analyst ratings
90%
of 30 ratingsMore NBIX News
Neurocrine Biosciences (NBIX) just kicked off a randomized, double blind, placebo controlled Phase 2 trial of NBI-1117568 in adults with Bipolar I manic episode...
Earlier in December 2025, Neurocrine Biosciences outlined a refreshed R&D strategy, spotlighting late-stage neuropsychiatry programs for major depressive disord...